期刊文献+

正交试验优化鼠疫活疫苗冻干稳定剂 被引量:1

Optimization of lyophilized stabilizer for plague vaccine with orthogonal design
下载PDF
导出
摘要 目的优化皮上划痕用鼠疫活疫苗的稳定剂配方。方法采用正交试验,以鼠疫杆菌冻干存活率为检测指标,分别对乳糖、谷氨酸钠、硫脲和尿素4种成分组成的稳定剂配方,以及乳糖、蔗糖、谷氨酸钠、硫脲和尿素5种成分组成的稳定剂配方进行优化。结果 4种成分组成的稳定剂最佳组合为乳糖7.5%、谷氨酸钠0.5%、硫脲1.0%、尿素0.1%(均为质量分数),此配方可使菌体的冻干存活率达到(68.49±6.19)%;5种成分组成的冻干稳定剂最佳组合为乳糖7.5%、蔗糖7.5%、谷氨酸钠0.5%、硫脲0.5%、尿素0.1%(均为质量分数),此配方可使菌体的冻干存活率达到(74.71±6.34)%,均高于现有稳定剂配方。结论优化的两种稳定剂均对鼠疫杆菌具有较好的保护作用。 Objective To select the optimum formulation of lyophilized stabilizer for plague live vaccine. Methods Using orthogonal design, viable count was used as an index, the four components formulation (containing lactose, sodium gluta- mate, thiourea and urea) was compared with the five components formulation ( add in sucrose ). Results In the best com- position conditions of 7.5% lactose, 0.5% sodium glutamate, 1.0% thiourea and 0.1% urea the survival cells rate can reach 68.49%. Under the best five component conditions of 7.5% lactose, 7.5% sucrose, 0.5% sodium glutamate, 0.5% thiourea and 0.1% urea the survival cells rate can reach 74.71%. Conclusions The two formulated stabilizers are optimized and they have the good protective effect for plague live vaccine.
出处 《微生物学免疫学进展》 2014年第6期19-23,共5页 Progress In Microbiology and Immunology
关键词 正交试验 皮上划痕用鼠疫活疫苗 稳定剂 优化 Orthogonal design Live plague vaccine Stabilizer Optimization
  • 相关文献

参考文献6

二级参考文献91

共引文献50

同被引文献13

  • 1TATE J E, BURTON H, BOSCHI-PINTO C, et al. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years betbre the introduction of universal rota- virus vaccination programmes analysis [J]. Lancet Infect Dis a systematic review and recta- 2012, 12 (2): 136-141.
  • 2KANG M S, JANG H, KIM M C, et al. Development of a stabilizer for lyophilization of an attenuated duck viral hepatitis vaccine [J]. Pouh Sci, 2010, 89 (6): 1167-1170.
  • 3REYNOLDS B, IZARD R S. Vaccine stabilizer method: US Patent 20, 050, 186, 22l [P]. 2005-8-25.
  • 4REYNOLDS B, IZARD R S. Vaccine stabilizer and method of use: US Patent 20, 030, 215, 455 [P]. 2003-11-20.
  • 5CLARK H F, BURKE C J, VOLKIN D B, et aL Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavinis vaccine in a new stabilizer/buffer liquid formulation [J]. Pediatric Infect Dis J, 2003, 22 (10): 914-920.
  • 6LEIGH S A, BRANTON S L, COLLIER S D. Stabilization of live Mycoplasma gallisept,:cum vaccines during vaccination with second-generation Spray-Vac vaccine stabilizer [J]. J Appl Poultry Res, 2008, 17 (2): 278-282.
  • 7DHERE R M, PISAL S S, ZADE J K. Stable, dried rotavirus vaccine, compositions and process for preparation thereof: US Patent 8, 795, 686 [P]. 2014-08-05.
  • 8PULLIAM B L. Rotavints preparations with excess calcium ions and high viscosities that ensure viability at elevated temeratures: US Patent 20, 140, 356, 396 [P]. 2014-12-04.
  • 9SUN T, LEVESQUE P M, BROWN A T, et al. Vaccine stabilizer: US Patent Application 13/355, 158 [P]. 2012-01- 20.
  • 10段凯,李黎.冻干乙型脑炎减毒活疫苗非动物源性稳定剂的配方及其缓冲液的筛选[J].中国生物制品学杂志,2012,25(11):1431-1433. 被引量:5

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部